WARRINGTON, Pa., Oct. 17, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today submitted its Complete Response to the May 2008 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA's guidelines provide that by October 31, the FDA will determine the classification of the submission and notify Discovery Labs of its target date for potential approval of Surfaxin. Discovery Labs believes that the FDA may designate the Complete Response as a Class 1 resubmission, which would result in a target review period of sixty-days and potential approval of Surfaxin in 2008.
